• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Michelle Seitz Appointed to MSCI Inc. Board of Directors

    8/1/24 6:45:00 AM ET
    $MSCI
    $SANA
    Real Estate
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MSCI alert in real time by email

    MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that Michelle Seitz, the former Chair and CEO of Russell Investments, has been appointed to serve as an independent director on MSCI's Board of Directors (the "Board"), effective August 5, 2024. Ms. Seitz will serve as a member of the Audit and Risk Committee of the Board. Ms. Seitz's appointment comes after an extensive search initiated last year.

    "Michelle has deep experience in the investment industry, having spent more than three decades in asset management and private wealth, both as a CEO and as an investor," said Henry A. Fernandez, Chairman and Chief Executive Officer of MSCI. "She has driven transformational growth while fostering an award-winning, client-centric culture. Her leadership experience, knowledge of the investment industry and ability to lead and grow large global organizations will all contribute meaningfully to the MSCI Board," added Mr. Fernandez.

    "MSCI is at the forefront of supporting clients as they navigate a complex and transforming investment landscape, and I am thrilled to be joining in their mission to bring greater transparency to financial markets," said Ms. Seitz. "The Board of MSCI is comprised of diverse and talented individuals, and I look forward to working closely with my fellow Board members and management to continue supporting our clients, shareholders, employees and the broader investment community."

    Michelle Seitz, a seasoned business executive and investor, is the Founder and CEO of MeydenVest Partners, a private investment and strategic advisory firm launched in 2022. Prior to this, she served as the Chair and CEO of Russell Investments, one of the world's largest asset management firms, where she enhanced profitability and scalability. Before Russell Investments, Ms. Seitz held various leadership roles at William Blair, including CEO of William Blair Investment Management, where she led the firm to achieve fivefold growth, establishing it as an internationally recognized global asset and wealth management firm. Currently, she also serves as a director on the board of SANA Biotechnology (NASDAQ:SANA). Ms. Seitz is a graduate of the Kelley School of Business at Indiana University, and is a Chartered Financial Analyst (CFA). She has been recognized as one of the most influential women in U.S. finance.

    About MSCI Inc.

    MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com. MSCI#IR

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI's control and that could materially affect actual results, levels of activity, performance or achievements.

    Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission ("SEC") on February 9, 2024 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI's underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this earnings release reflects MSCI's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI's operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward- looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240801030862/en/

    Get the next $MSCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSCI
    $SANA

    CompanyDatePrice TargetRatingAnalyst
    MSCI Inc.
    $MSCI
    2/17/2026$700.00Buy
    BofA Securities
    MSCI Inc.
    $MSCI
    10/1/2025$650.00Buy
    Seaport Research Partners
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    MSCI Inc.
    $MSCI
    7/25/2025$650.00Mkt Perform → Outperform
    Raymond James
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    MSCI Inc.
    $MSCI
    4/10/2025$585.00Neutral
    BofA Securities
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    More analyst ratings

    $MSCI
    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ashe Robert G. bought $1,999,556 worth of shares (3,681 units at $543.21) (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/20/26 4:04:06 PM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $3,560,239 worth of shares (6,800 units at $523.56), increasing direct ownership by 0.46% to 1,493,847 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/17/26 6:02:45 PM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $6,701,732 worth of shares (12,500 units at $536.14), increasing direct ownership by 0.69% to 1,487,047 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    12/9/25 6:38:10 AM ET
    $MSCI
    Real Estate

    $MSCI
    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MSCI Equity Indexes February 2026 Index Review

    MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the February 2026 Index Review for the MSCI Equity Indexes. All changes will be implemented as of the close of February 27, 2026. Highlights include: MSCI Global Standard Indexes: Sixty-three securities will be added to and 61 securities will be deleted from the MSCI ACWI Index. The three largest additions to the MSCI World Index measured by full company market capitalization will be AST SpaceMobile A (USA), Coherent Corp (USA) and FTAI Aviation (USA). The three largest additions to the MSCI Emerging Markets Index measured by full compan

    2/10/26 7:10:00 PM ET
    $MSCI
    Real Estate

    MSCI to Participate in Upcoming Investor Conferences

    MSCI Inc. ("MSCI" or the "Company") (NYSE:MSCI) announced today that Andrew Wiechmann, Chief Financial Officer, will be participating in fireside chats at the following investor conferences: UBS Financial Services Conference on Monday, February 9, 2026 at 9:40AM Eastern Time Raymond James Annual Institutional Investors Conference on Tuesday, March 3, 2026 at 8:40AM Eastern Time A live webcast and replay of these events will be available on the events and presentations section of MSCI's Investor Relations homepage at https://ir.msci.com/events-and-presentations. About MSCI Inc. MSCI Inc. (NYSE:MSCI) strengthens global markets by connecting participants across the financial ecosy

    2/4/26 11:50:00 AM ET
    $MSCI
    Real Estate

    $MSCI
    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ashe Robert G. bought $1,999,556 worth of shares (3,681 units at $543.21) (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/20/26 4:04:06 PM ET
    $MSCI
    Real Estate

    SEC Form 4 filed by EVP, Chief Financial Officer Piper Brian

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/18/26 4:35:39 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Piper Brian

    3 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/18/26 4:33:51 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MSCI
    $SANA
    SEC Filings

    View All

    Sana Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

    2/17/26 9:07:30 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by MSCI Inc.

    10-K - MSCI Inc. (0001408198) (Filer)

    2/6/26 2:54:21 PM ET
    $MSCI
    Real Estate

    MSCI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MSCI Inc. (0001408198) (Filer)

    1/28/26 4:32:25 PM ET
    $MSCI
    Real Estate

    $MSCI
    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on MSCI with a new price target

    BofA Securities resumed coverage of MSCI with a rating of Buy and set a new price target of $700.00

    2/17/26 7:31:33 AM ET
    $MSCI
    Real Estate

    Seaport Research Partners initiated coverage on MSCI with a new price target

    Seaport Research Partners initiated coverage of MSCI with a rating of Buy and set a new price target of $650.00

    10/1/25 9:36:04 AM ET
    $MSCI
    Real Estate

    Wedbush initiated coverage on Sana Biotechnology with a new price target

    Wedbush initiated coverage of Sana Biotechnology with a rating of Outperform and set a new price target of $5.00

    9/24/25 7:58:10 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MSCI
    $SANA
    Leadership Updates

    Live Leadership Updates

    View All

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MSCI Announces Baer Pettit to Retire as President

    Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leader

    11/17/25 7:00:00 AM ET
    $MSCI
    Real Estate

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $MSCI
    $SANA
    Financials

    Live finance-specific insights

    View All

    MSCI Schedules Earnings Call to Review Fourth Quarter and Full Year 2025 Results

    MSCI Inc. ("MSCI" or the "Company") (NYSE:MSCI) announced today that it will release its results for the fourth quarter and full year 2025 on Wednesday, January 28, 2026, before the market opens. A copy of the earnings release, as well as an earnings presentation and a quarterly update, will be made available on MSCI's Investor Relations website. MSCI's senior management will review the fourth quarter and full year 2025 results on Wednesday, January 28, 2026, at 11:00 AM Eastern Time. To listen to the live event via webcast, visit the events and presentations section of MSCI's Investor Relations website, https://ir.msci.com/events-and-presentations. Participants who wish to join via telep

    1/6/26 9:00:00 AM ET
    $MSCI
    Real Estate

    MSCI Schedules Earnings Call to Review Third Quarter 2025 Results

    MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it will release its results for the third quarter 2025 on Tuesday, October 28, 2025, before the market opens. A copy of the earnings release, as well as an earnings presentation and a quarterly update, will be made available on MSCI's Investor Relations website. MSCI's senior management will review the third quarter 2025 results on Tuesday, October 28, 2025, at 11:00 AM Eastern Time. To listen to the live event via webcast, visit the events and presentations section of MSCI's Investor Relations website, https://ir.msci.com/events-and-presentat

    10/3/25 9:20:00 AM ET
    $MSCI
    Real Estate

    Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

    8/6/25 7:00:00 AM ET
    $MCRB
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $MSCI
    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care